Global DNA Probes-Based Diagnostics Industry

Jul 03, 2012, 07:24 ET from Reportlinker

NEW YORK, July 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global DNA Probes-Based Diagnostics Industry

http://www.reportlinker.com/p098404/Global-DNA-Probes-Based-Diagnostics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnosti

This report analyzes the worldwide markets for DNA Probes-based Diagnostics in US$ Million by the following Application Areas: Infectious Diseases, Cancer Testing, Genetic Predisposition, Identity/Forensics, Molecular HLA (Human Leukocyte Antigen) Typing, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 63 companies including many key and niche players such as Abbott Laboratories, Affymetrix, Inc., Becton, Dickinson & Company, Beckman Coulter, Inc., bioMerieux, Celera Group, Gen-Probe Incorporated, Genzyme Corporation, Luminex Molecular Diagnostics, QIAGEN, Roche Diagnostics, and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-3Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3Infectious Diseases I-4Cancer I-4Genetic Predisposition I-4Identity/Forensics I-4Molecular HLA Testing I-4Other Diagnostic Applications I-4II. EXECUTIVE SUMMARY

1. MARKET DYNAMICS II-1

Industry Overview II-1

DNA Probes: Robust Growth Ahead II-1

Decoding the Genetic Puzzle II-1

Advantages of DNA-Probe Tests II-2

Growth Drivers in a Nutshell II-2

Growth Inhibitors in a Nutshell II-2

Genetic Profiling of Pathogens: A Road Less Traveled II-3

Roche's Entry into the Hall of Molecular Fame II-3

DNA Technology: An Evolutionary Scan II-4

An Era of Excellence: Tracking Landmark Breakthroughs in DNA

Diagnostics II-4

Opportunities II-5

Market Trends/Issues II-6

DNA Tests: Finding Use in Numerous Applications II-6

World's Aging Population Drives the Popularity of DNA-Probe

Tests II-6

Reimbursements: "Under the Umbrella" II-6

Evolution of New & Virulent Infectious Agents II-7

The Enlightened Consumer of the 21st Century II-7

Challenges In Widespread Deployment of DNA Based Diagnostics II-7

Miniaturization: An Uphill Task II-7

Improvements in Assay Capabilities II-8

Information Handling & Processing: The Soft Side of Diagnostics II-8

Integration: The Ultimate Challenge II-8

The United States: Unraveling the Country's Edge in DNA based

Diagnostics II-9

2. DNA PROBES-BASED DIAGNOSTICS - A PRIMER II-10Diagnostic Gene Detection Products II-10Molecular Diagnostics: A Powerful Disease Detection Tool II-10DNA Probes-Based Products II-11Direct Detection of Target Sequence II-11Nucleic Acid Amplification II-11Gene Detection Using DNA Chips II-11Gene Detection by DNA Sequencing II-12The Dynamics of Key Enabling Technologies II-12In Situ Hybridization II-12PCR: Polymerase Chain Reaction II-12Chemiluminescence II-13Gen-Probe Tigris II-13DNA Chips II-13Key Players II-13Players in Molecular Diagnostics Market II-13Molecular Diagnostics - A Primer II-14Implications for Clinical Diagnostics II-14Need of the Hour II-14Molecular Diagnostics: Marking the Convergence of NumerousTechnologies II-14Impact of the Human Genome Project II-15Molecular Diagnostics: Domain of the Developed Countries II-15"Tailored Patient Management": An Epitomized Future ofMolecular Diagnostics II-15Futuristics: A Rumination II-15

3. PRODUCT OVERVIEW II-17

Background II-17

Gene Probe Technology II-17

What is DNA? II-17

DNA Probes II-17

Miniaturization: A Revolutionary Method in DNA Analysis II-18

Gene Chip Technology II-18

DNA Chips II-18

Chromosome Painting Probes II-18

Diagnostic Applications Based on DNA Probes: An Overview II-19

Infectious Diseases II-19

Respiratory Tract Infections II-19

Diagnosis of Mycoplasma II-19

DNA Probes to Detect Legionella Pneumophila II-19

Detecting Tuberculosis Through Rapid Diagnostic Tests II-19

How the Technique Works II-20

Limitations II-20

Sexually Transmitted Diseases (STDs) II-20

HIV II-20

HTLV-1 Testing II-20

Hepatitis Testing II-20

Chlamydia DNA Probes II-21

Detection of Intestinal Parasites II-21

Entamoeba Histolytica II-21

Salmonella II-21

Identity/Forensics II-21

DNA Profiling: A Key Forensic Tool II-21

DNA-Based Forensic Diagnostics II-22

Tracing Human Origins II-22

Genetic Predisposition II-22

Molecular HLA Testing II-22

Human Leukocyte Antigen (HLA) Typing II-22

Cancer Testing II-23

Cancer: A Deadly Disease Afflicting Millions II-23

Slow Detoxifiers: Potential Cancer Candidates II-23

Improving Cancer Surgery Through Diagnostic Tests II-23

Types of Cancer II-24

Chronic Lymphocytic Leukemia (CLL) II-24

Breast Cancer II-24

PCR Screening Technology for Breast Cancer II-24

Eye Cancers II-24

DNA Probes to Detect Retinoblastoma II-24

Others II-24

The Ames test II-25

Genetic Testing II-25

Other Diagnostic Applications II-25

Cystic Fibrosis II-25

Malaria Testing II-26

Detection of Multidrug Resistance II-26

Bacterial Resistance to Antibiotics II-26

DNA Probes for Agriculture II-26

4. PRODUCT INTRODUCTIONS/INNOVATIONS II-27LifeTechnologies Launches Applied Biosystems AutoMate Express™ II-27OralDNA Labs™ Launches Two Dental Molecular Tests II-27

5. PRODUCT INTRODUCTIONS/INNOVATIONS - A HISTORIC PERSPECTIVE BUILDER II-28

Luminex Molecular Introduces New xTAG™ Respiratory Viral Panel II-28

Gen-Probe Introduces Aptima HPV Assay in Europe II-28

Genzyme Genetics Introduces Prenatal Diagnosis and Carrier

Testing II-28

Affymetrix Launches New Cytogenetic Solution II-29

Genekam Biotech Develops New Commercial DNA-Test to Detect

Bird Flu II-29

Seegene Launches Innovative DNA Test to Detect HPVs II-30

deCODE Introduces deCODE T2 II-30

InterGenetics Introduces OncoVue II-30

bioMerieux Unveils VIDAS C II-30

bioMerieux Unveils NucliSENS EasyQ HPV II-31

Applied Biosystems Launches SOLiD System II-31

bioMerieux Introduces VIDAS® NT-proBNP II-31

Abbott Molecular Rolls Out Six DNA Probes II-32

PerkinElmer Launches Two New Multiplexing Platforms for

Genomic Research II-32

Kreatech Introduces First Complete Whole Genome Amplification Kit II-32

Relative Genetics Introduces DNA Testing Services II-33

Sorenson Launches Over-the-counter Paternity Test Kits II-33

Kimball Genetics Introduces Warfarin Sensitivity DNA Test II-34

bioMerieux Introduces TEMPO EB II-34

Gen-Probe Launches PCA3 Assay II-34

Genzyme Launches New KRAS Mutation Analysis II-34

BD Launches New BD Viper System for Automating Molecular

Diagnostic Testing Process II-35

Affymetrix Unveils New GeneChip® Scanner with Higher Capacity

Scanning II-35

Genzyme Introduces EGFR Mutation Assay for Detecting Mutations II-35

6. RECENT INDUSTRY ACTIVITY II-36Danaher Acquires Beckman Coulter II-36QIAGEN Partners with Genome Diagnostics II-36ZyGEM Snaps Up MicroLab Diagnostics II-36Metropolis Healthcare Partners with DDC II-37China Medical Technologies Obtains SFDA Approval II-37Nanobac Inks Merger Agreement with Eureka Genomics II-37Genzyme Enters into Licensing Agreement with Moffitt CancerCenter II-38Xceed Molecular Offers Gen-Probe License for Flow-Thru Chip®Technology II-38Dako Denmark's TOP2A FISH pharmDx Receives FDA Approval II-38Roche Diagnostics Receives Approval for Elecsys Anti-HCV Assay II-39bioMerieux and FIND Ink Memorandum of Understanding II-39BD Establishes Second Production Facility in China II-39Shanghai Kehua Bio-engineering and bioMerieux Establish JointVenture II-39Quidel to Enter into Alliance with bioMerieux II-40Beckman Coulter Bags Rights to Hepatitis C Virus Test fromSiemens II-40Affymetrix Enters into Partnership with Pathwork Diagnostics II-41Luminex Signs Distribution and Sales Agreement with Abbott II-41Gen-Probe to Acquire Innogenetics II-42Biocept to Introduce I.D.Rh(D) II-42DNA Testing Systems and DNAPrint Genomics Sign Sales Agreement II-42

7. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-44

Siemens Acquires Dade Behring II-44

Sorenson Genomics Acquires Identigene II-44

BioServe Takes Over Genomics Collaborative II-44

Illumina Acquires Solexa II-45

QIAGEN to Merge With eGene II-45

NorDiag Acquires Genpoint II-45

Cepheid Takes Over Sangtec Molecular Diagnostics II-46

3M Enters into Collaboration with Gen-Probe II-46

Luminex Corporation Completes Acquisition of Tm Bioscience II-46

Ventana Medical Systems and C-Path to Collaborate with NCI and

FDA II-47

Ipsen and bioMerieux Enter into Theragnostics Agreement II-47

Celera Acquires Atria Genetics II-48

Celera Acquires Berkeley HeartLab II-48

Beckman Coulter Enters into Partnership II-49

Affymetrix Partners with IPSOGEN for In-Vitro Diagnostic

Cancer Testing II-49

Ventana Medical Systems Collaborates with Genentech II-49

Siemens Medical Solutions Acquires Bayer's Diagnostic Division II-50

Orchid Cellmark Acquires ReliaGene Technologies II-50

GATC Enters into Collaboration for Developing DNA-based

Diagnostic Test II-50

Genetic Solutions and Catapult Merge to Establish Catapult

Genetics II-51

Grant Life Sciences Signs MoU with Alphagenics Diaco

Biotechnologies II-51

Gen-Probe and Millipore Ink Agreement to Market MTC-NI Test II-52

QIAGEN Acquires Digene Corporation II-52

BD Diagnostics and Quest Diagnostics Sign Agreement for BD

Viper™ System II-53

Enzo Biochem Plans to Produce Single Copy DNA Probes II-53

Affymetrix Signs Two Agreements with Sysmex II-53

Affymetrix and Partners HealthCare Enter into Collaboration II-54

Affymetrix and Epigenomics Enter into an Agreement II-54

Roche Introduces Elecsys TORCH Assays II-55

QIAGEN to Take Over Gentra II-55

LGC Acquires AGOWA to Extend German Operations II-55

ENZ Receives Patent for Phosphate Labeling for Medical

Research & DNA Diagnostic Products II-56

TMC Achieves CE Mark for its Tag-It Cystic Fibrosis Test Kit II-56

Toshiba Licenses Electrochemical Detection Technology to Antara II-56

Affymetrix Licenses Multiple Patents to Invitrogen II-57

Abbott Enters into Agreement with ALSI for Licensing ProGRP

Biomarker II-57

QIAGEN in Protein Crystallography Co-Marketing Agreement with

ActiveSight II-57

Warnex Acquires Pro-DNA Diagnostic II-58

Celera Genomics Gains Complete Ownership of Celera Diagnostics II-58

Gen-Probe Licenses Exclusive Rights for Diagnostic Tests

Development from University of Michigan II-58

QIAGEN Enters into Licensing Agreement with Applied Biosystems

for Real-Time PCR Technologies II-59

IGC Collaborates with Roche for Cancer Biomarker Discovery II-59

Affymetrix Acquires ParAllele BioScience II-59

QIAGEN Enters into Distribution Agreement with Osmetech

Molecular Diagnostics II-60

GlaxoSmithKline Acquires Canada-Based ID Biomedical Corp. II-60

Gen-Probe Obtains FDA Approval for Marketing APTIMA II-60

Gen-Probe Signs Purchasing Agreement with Roche II-60

MP Biomedicals Acquires Qbiogene II-61

Roche Diagnostics Receives FDA Approval for AmpliChip CYP450 Test II-61

Ventana Launches ISH Tests II-61

8. FOCUS ON SELECT GLOBAL PLAYERS II-62Abbott Molecular (US) II-62Affymetrix, Inc. (US) II-62Becton, Dickinson & Company (US) II-62Beckman Coulter, Inc. (US) II-63bioMerieux (France) II-63Celera Group (US) II-63Gen-Probe Incorporated (US) II-64Genzyme Corporation (US) II-64Luminex Molecular Diagnostics (Canada) II-64QIAGEN (US) II-64Roche Diagnostics (Switzerland) II-65Siemens Healthcare Diagnostics, Inc. (US) II-65

9. GLOBAL MARKET PERSPECTIVE II-66

Table 1: World Recent Past, Current & Future Analysis for DNA

Probes-based Diagnostics by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan) and Latin

American Markets Independently Analyzed with Annual Revenue

Figures in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) II-66

Table 2: World Historic Review for DNA Probes-basedDiagnostics by Geographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Latin American MarketsIndependently Analyzed with Annual Revenue Figures in US$Million for Years 2003 through 2008 (includes correspondingGraph/Chart) II-67

Table 3: World 15-Year Perspective for DNA Probes-based

Diagnostics by Geographic Region - Percentage Breakdown of

Revenues for US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan) and Latin American Markets for Years 2003,

2011 & 2017 (includes corresponding Graph/Chart) II-68

Table 4: World Recent Past, Current & Future Analysis for DNAProbes-based Diagnostics (Infectious Disease Diagnosis) byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan) and Latin American Markets IndependentlyAnalyzed with Annual Revenue Figures in US$ Million for Years2009 through 2017 (includes corresponding Graph/Chart) II-69

Table 5: World Historic Review for DNA Probes-based

Diagnostics (Infectious Disease Diagnosis) by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), and Latin American Markets Independently Analyzed with

Annual Revenue Figures in US$ Million for Years 2003 through

2008 (includes corresponding Graph/Chart) II-70

Table 6: World 15-Year Perspective for DNA Probes-basedDiagnostics (Infectious Disease Diagnosis) by GeographicRegion - Percentage Breakdown of Revenues for US, Canada,Japan, Europe, Asia-Pacific (excluding Japan) and LatinAmerican Markets for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) II-71

Table 7: World Recent Past, Current & Future Analysis for DNA

Probes-based Diagnostics (Cancer Diagnosis) by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan) and Latin American Markets Independently Analyzed with

Annual Revenue Figures in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) II-72

Table 8: World Historic Review for DNA Probes-basedDiagnostics (Cancer Diagnosis) by Geographic Region - US,Canada, Japan, Europe, Asia-Pacific (excluding Japan), andLatin American Markets Independently Analyzed with AnnualRevenue Figures in US$ Million for Years 2003 through 2008(includes corresponding Graph/Chart) II-73

Table 9: World 15-Year Perspective for DNA Probes-based

Diagnostics (Cancer Diagnosis) by Geographic Region -

Percentage Breakdown of Revenues for US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan) and Latin American

Markets for Years 2003, 2011 & 2017 (includes corresponding

Graph/Chart) II-74

Table 10: World Recent Past, Current & Future Analysis for DNAProbes-based Diagnostics (Genetic Predisposition Diagnosis) byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan) and Latin American Markets IndependentlyAnalyzed with Annual Revenue Figures in US$ Million for Years2009 through 2017 (includes corresponding Graph/Chart) II-75

Table 11: World Historic Review for DNA Probes- based

Diagnostics (Genetic Predisposition Diagnosis) by Geographic

Region - US, Canada, Japan, Europe, Asia-Pacific (excluding

Japan), and Latin American Markets Independently Analyzed with

Annual Revenue Figures Figures in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) II-76

Table 12: World 15-Year Perspective for DNA Probes- basedDiagnostics (Genetic Predisposition Diagnosis) by GeographicRegion - Percentage Breakdown of Revenues for US, Canada,Japan, Europe, Asia-Pacific (excluding Japan) and LatinAmerican Markets for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) II-77

Table 13: World Recent Past, Current & Future Analysis for DNA

Probes-based Diagnostics (Identity/Forensics Diagnosis) by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan) and Latin American Markets Independently

Analyzed with Annual Revenue Figures in US$ Million for Years

2009 through 2017 (includes corresponding Graph/Chart) II-78

Table 14: World Historic Review for DNA Probes- basedDiagnostics (Identity/Forensics Diagnosis) by GeographicRegion - US, Canada, Japan, Europe, Asia-Pacific (excludingJapan), and Latin American Markets Independently Analyzed withAnnual Revenue Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) II-79

Table 15: World 15-Year Perspective for DNA Probes-based

Diagnostics (Identity/Forensics Diagnosis) by Geographic

Region - Percentage Breakdown of Revenues for US, Canada,

Japan, Europe, Asia-Pacific (excluding Japan) and Latin

American Markets for Years 2003, 2011 & 2017 (includes

corresponding Graph/Chart) II-80

Table 16: World Recent Past, Current & Future Analysis for DNAProbes-based Diagnostics (Molecular HLA Testing) by GeographicRegion - US, Canada, Japan, Europe, Asia-Pacific (excludingJapan) and Latin American Markets Independently Analyzed withAnnual Revenue Figures in US$ Million for Years 2009 through2017 (includes corresponding Graph/Chart) II-81

Table 17: World Historic Review for DNA Probes-based

Diagnostics (Molecular HLA Testing) by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific (excluding Japan), and

Latin American Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) II-82

Table 18: World 15-Year Perspective for DNA Probes-basedDiagnostics (Molecular HLA) by Geographic Region - PercentageBreakdown of Revenues for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan) and Latin American Markets forYears 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-83

Table 19: World Recent Past, Current & Future Analysis for DNA

Probes-based Diagnostics in Others Types of Diagnosis by

Geographic Region - US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan) and Latin American Markets Independently

Analyzed with Annual Revenue Figures in US$ Million for Years

2009 through 2017 (includes corresponding Graph/Chart) II-84

Table 20: World Historic Review for DNA Probes-basedDiagnostics in Others Types of Diagnosis by Geographic Region -US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),and Latin American Markets Independently Analyzed with AnnualRevenue Figures in US$ Million for Years 2003 through 2008(includes corresponding Graph/Chart) II-85

Table 21: World 15-Year Perspective for DNA Probes- based

Diagnostics in Others Types of Diagnosis by Geographic Region -

Percentage Breakdown of Revenues for US, Canada, Japan,

Europe, Asia-Pacific (excluding Japan) and Latin American

Markets for Years 2003, 2011 & 2017 (includes corresponding

Graph/Chart) II-86

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

DNA-Based Diagnostic and Test Market: Progress towards a New

Phase III-1

DNA-Based Diagnostic Tests Picks Up Pace in New Streams III-1

Rise of DNA-Based Home Testing Kits Market III-2

Focus on Select Key Players III-2

B.Market Analytics III-3

Table 22: The US Recent Past, Current & Future Analysis for

DNA Probes-based Diagnostics by Application Area -

Infectious Diseases, Cancer, Genetic Predisposition,

Identity/Forensics, Molecular HLA Testing, and Others

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-3

Table 23: The US Historic Review for DNA Probes-basedDiagnostics by Application Area - Infectious Diseases,Cancer, Genetic Predisposition, Identity / Forensics,Molecular HLA Testing, and Others Markets IndependentlyAnalyzed with Annual Revenue Figures in US$ Million forYears 2003 through 2008 (includes corresponding Graph/Chart) III-4

Table 24: The US 15-Year Perspective for DNA Probes- based

Diagnostics by Application Area Percentage Breakdown of

Revenues for Infectious Diseases, Cancer, Genetic

Predisposition, Identity/Forensics, Molecular HLA Testing,

and Others Markets for Years 2003, 2011 & 2017 (includes

corresponding Graph/Chart) III-5

2. CANADA III-6Market Analytics III-6Table 25: Canadian Recent Past, Current & Future Analysisfor DNA Probes-based Diagnostics by Application Area -Infectious Diseases, Cancer, Genetic Predisposition,Identity/Forensics, Molecular HLA Testing, and OthersMarkets Independently Analyzed with Annual Revenue Figuresin US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) III-6

Table 26: Canadian Historic Review for DNA Probes-based

Diagnostics by Application Area - Infectious Diseases,

Cancer, Genetic Predisposition, Identity/Forensics,

Molecular HLA Testing, and Others Markets Independently

Analyzed with Annual Revenue Figures in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) III-7

Table 27: Canadian 15-Year Perspective for DNA Probes-basedDiagnostics by Application Area Percentage Breakdown ofRevenues for Infectious Diseases, Cancer, GeneticPredisposition, Identity/Forensics, Molecular HLA Testing,and Others Markets for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) III-8

3. JAPAN III-9

Market Analytics III-9

Table 28: Japanese Recent Past, Current & Future Analysis

for DNA Probes-based Diagnostics by Application Area -

Infectious Diseases, Cancer, Genetic Predisposition,

Identity/Forensics, Molecular HLA Testing, and Others

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-9

Table 29: Japanese Historic Review for DNA Probes-basedDiagnostics by Application Area - Infectious Diseases,Cancer, Genetic Predisposition, Identity/Forensics,Molecular HLA Testing, and Others Markets IndependentlyAnalyzed with Annual Revenue Figures in US$ Million forYears 2003 through 2008 (includes corresponding Graph/Chart) III-10

Table 30: Japanese 15-Year Perspective for DNA Probes-based

Diagnostics by Application Area Percentage Breakdown of

Revenues for Infectious Diseases, Cancer, Genetic

Predisposition, Identity/Forensics, Molecular HLA Testing,

and Others Markets for Years 2003, 2011 & 2017 (includes

corresponding Graph/Chart) III-11

4. EUROPE III-12Market Analytics III-12Table 31: European Recent Past, Current & Future Analysisfor DNA Probes-based Diagnostics by Geographic Region -France, Germany, Italy, UK and Rest of Europe MarketsIndependently Analyzed with Annual Revenue Figures in US$Million for Years 2009 through 2017 (includes correspondingGraph/Chart) III-12

Table 32: European Historic Review for DNA Probes- based

Diagnostics by Geographic Region - France, Germany, Italy,

UK and Rest of Europe Markets Independently Analyzed with

Annual Revenue Figures in US$ Million for Years 2003 through

2008 (includes corresponding Graph/Chart) III-13

Table 33: European 15-Year Perspective for DNA Probes-basedDiagnostics by Geographic Region - Percentage Breakdown ofRevenues for France, Germany, Italy, UK and Rest of EuropeMarkets for Years 2003, 2011 & 2017 (includes correspondingGraph/Chart) III-14

Table 34: European Recent Past, Current & Future Analysis

for DNA Probes-based Diagnostics by Application Area -

Infectious Diseases, Cancer, Genetic Predisposition,

Identity/Forensics, Molecular HLA Testing, and Others

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-15

Table 35: European Historic Review for DNA Probes- basedDiagnostics by Application Area - Infectious Diseases,Cancer, Genetic Predisposition, Identity/ Forensics,Molecular HLA Testing, and Others Markets IndependentlyAnalyzed with Annual Revenue Figures in US$ Million forYears 2003 through 2008 (includes corresponding Graph/Chart) III-16

Table 36: European 15-Year Perspective for DNA Probes-based

Diagnostics by Application Area Percentage Breakdown of

Revenues for Infectious Diseases, Cancer, Genetic

Predisposition, Identity/Forensics, Molecular HLA Testing,

and Others Markets for Years 2003, 2011 & 2017 (includes

corresponding Graph/Chart) III-17

4a. FRANCE III-18Market Analytics III-18Table 37: French Recent Past, Current & Future Analysis forDNA Probes-based Diagnostics by Application Area -Infectious Diseases, Cancer, Genetic Predisposition,Identity/Forensics, Molecular HLA Testing, and OthersMarkets Independently Analyzed with Annual Revenue Figuresin US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) III-18

Table 38: French Historic Review for DNA Probes- based

Diagnostics by Application Area - Infectious Diseases,

Cancer, Genetic Predisposition, Identity/ Forensics,

Molecular HLA Testing, and Others Markets Independently

Analyzed with Annual Revenue Figures in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) III-19

Table 39: French 15-Year Perspective for DNA Probes- basedDiagnostics by Application Area Percentage Breakdown ofRevenues for Infectious Diseases, Cancer, GeneticPredisposition, Identity/Forensics, Molecular HLA Testing,and Others Markets for 2003, 2011 & 2017 (includescorrespondingGraph/Chart) III-20

4b. GERMANY III-21

Market Analytics III-21

Table 40: German Recent Past, Current & Future Analysis for

DNA Probes-based Diagnostics by Application Area -

Infectious Diseases, Cancer, Genetic Predisposition,

Identity/Forensics, Molecular HLA Testing, and Others

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-21

Table 41: German Historic Review for DNA Probes-basedDiagnostics by Application Area - Infectious Diseases,Cancer, Genetic Predisposition, Identity/Forensics,Molecular HLA Testing, and Others Markets IndependentlyAnalyzed with Annual Revenue Figures in US$ Million forYears 2003 through 2008 (includes corresponding Graph/Chart) III-22

Table 42: German 15-Year Perspective for DNA Probes-based

Diagnostics by Application Area Percentage Breakdown of

Revenues for Infectious Diseases, Cancer, Genetic

Predisposition, Identity/Forensics, Molecular HLA Testing,

and Others Markets for 2003, 2011 & 2017 (includes

corresponding Graph/Chart) III-23

4c. ITALY III-24Market Analytics III-24Table 43: Italian Recent Past, Current & Future Analysis forDNA Probes-based Diagnostics by Application Area -Infectious Diseases, Cancer, Genetic Predisposition,Identity/Forensics, Molecular HLA Testing, and OthersMarkets Independently Analyzed with Annual Revenue Figuresin US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) III-24

Table 44: Italian Historic Review for DNA Probes-based

Diagnostics by Application Area - Infectious Diseases,

Cancer, Genetic Predisposition, Identity / Forensics,

Molecular HLA Testing, and Others Markets Independently

Analyzed with Annual Revenue Figures in US$ Million for

Years 2003 through 2008 (includes corresponding Graph/Chart) III-25

Table 45: Italian 15-Year Perspective for DNA Probes- basedDiagnostics by Application Area - Percentage Breakdown ofRevenues for Infectious Diseases, Cancer, GeneticPredisposition, Identity/Forensics, Molecular HLA Testing,and Others Markets for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) III-26

4d. THE UNITED KINGDOM III-27

Market Analytics III-27

Table 46: The UK Recent Past, Current & Future Analysis for

DNA Probes-based Diagnostics by Application Area -

Infectious Diseases, Cancer, Genetic Predisposition,

Identity/Forensics, Molecular HLA Testing, and Others

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-27

Table 47: The UK Historic Review for DNA Probes-basedDiagnostics by Application Area - Infectious Diseases,Cancer, Genetic Predisposition, Identity/Forensics,Molecular HLA Testing, and Others Markets IndependentlyAnalyzed with Annual Revenue Figures in US$ Million forYears 2003 through 2008 (includes corresponding Graph/Chart) III-28

Table 48: The UK 15-Year Perspective for DNA Probes- based

Diagnostics by Application Area - Percentage Breakdown of

Revenues for Infectious Diseases, Cancer, Genetic

Predisposition, Identity/Forensics, Molecular HLA Testing,

and Others Markets for Years 2003, 2011 & 2017 (includes

corresponding Graph/Chart) III-29

4e. REST OF EUROPE III-30Market Analytics III-30Table 49: Rest of European Recent Past, Current & FutureAnalysis for DNA Probes-based Diagnostics by ApplicationArea - Infectious Diseases, Cancer, Genetic Predisposition,Identity/Forensics, Molecular HLA Testing, and OthersMarkets Independently Analyzed with Annual Revenue Figuresin US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) III-30

Table 50: Rest of European Historic Review for DNA

Probes-based Diagnostics by Application Area - Infectious

Diseases, Cancer, Genetic Predisposition, Identity/

Forensics, Molecular HLA Testing, and Others Markets

Independently Analyzed with Annual Revenue Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) III-31

Table 51: Rest of European 15-Year Perspective for DNAProbes-based Diagnostics by Application Area - PercentageBreakdown of Revenues for Infectious Diseases, Cancer,Genetic Predisposition, Identity/Forensics, Molecular HLATesting, and Others Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart) III-32

5. ASIA-PACIFIC III-33

Market Analytics III-33

Table 52: Asia-Pacific Recent Past, Current & Future

Analysis for DNA Probes-based Diagnostics by Application

Area - Infectious Diseases, Cancer, Genetic Predisposition,

Identity/Forensics, Molecular HLA Testing, and Others

Markets Independently Analyzed with Annual Revenue Figures

in US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) III-33

Table 53: Asia-Pacific Historic Review for DNA Probes-basedDiagnostics by Application Area - Infectious Diseases,Cancer, Genetic Predisposition, Identity/Forensics,Molecular HLA Testing, and Others Markets IndependentlyAnalyzed with Annual Revenue Figures in US$ Million forYears 2003 through 2008 (includes corresponding Graph/Chart) III-34

Table 54: Asia-Pacific 15-Year Perspective for DNA

Probes-based Diagnostics by Application Area - Percentage

Breakdown of Revenues for Infectious Diseases, Cancer,

Genetic Predisposition, dentity/ Forensics, Molecular HLA

Testing, and Others Markets for Years 2003, 2011 & 2017

(includes corresponding Graph/Chart) III-35

6. LATIN AMERICA III-36Market Analytics III-36Table 55: Latin American Recent Past, Current & FutureAnalysis for DNA Probes-based Diagnostics by ApplicationArea - Infectious Diseases, Cancer, Genetic Predisposition,Identity/Forensics, Molecular HLA Testing, and OthersMarkets Independently Analyzed with Annual Revenue Figuresin US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) III-36

Table 56: Latin American Historic Review for DNA

Probes-based Diagnostics by Application Area - Infectious

Diseases, Cancer, Genetic Predisposition, Identity/

Forensics, Molecular HLA Testing, and Others Markets

Independently Analyzed with Annual Revenue Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) III-37

Table 57: Latin American 15-Year Perspective for DNAProbes-based Diagnostics by Application Area - PercentageBreakdown of Revenues for Infectious Diseases, Cancer,Genetic Predisposition, dentity/ Forensics, Molecular HLATesting, and Others Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart) III-38IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 63 (including Divisions/Subsidiaries - 79)

------------------------------------------Region/Country Players------------------------------------------The United States 51Canada 6Japan 2Europe 18France 1Germany 8The United Kingdom 3Italy 1Rest of Europe 5Asia-Pacific (Excluding Japan) 2------------------------------------------To order this report:Diagnostics Industry: Global DNA Probes-Based Diagnostics IndustryMore  Market Research ReportCheck our  Industry Analysis and Insights__________________________

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com